PFE — Pfizer Inc.

Pfizer (PFE) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $15 billion for Q2 2026, exceeding expectations with a 1% operational increase year-over-year. Excluding COVID products, operational revenue growth was 5%.
• Adjusted Diluted EPS: $0.77, also above expectations, reflecting strong non-COVID revenue performance and cost discipline.
• COVID-19 Revenue: Revised guidance for COVID revenues down to approximately $4 billion, impacted by low infection rates.
• Cost Management: Adjusted gross margin was 76%. Total adjusted operating expenses were $6.1 billion, a 4% operational increase year-over-year.

2. Strategic Updates and Business Highlights

• Acquisitions: Strong revenue growth from acquired products (25% operational growth) driven by Seagen, Metsera, and Biohaven. Notable performance from Seagen's legacy portfolio with a 21% year-over-year increase.
• Pipeline Progress: Significant advancements in R&D with 3 regulatory approvals, 6 key data readouts, and 8 pivotal study starts in H1 2026. Focus areas include oncology and obesity treatments.
• AI Integration: Pfizer is leveraging AI to enhance R&D productivity and operational efficiency, with plans to build an AI-native R&D organization.

3. Forward Guidance and Outlook

• Revenue Guidance: Midpoint raised by $500 million for full-year 2026 to a range of $60.5 billion to $62.5 billion, driven by strong non-COVID product performance.
• Adjusted EPS Guidance: Reaffirmed at $2.80 to $3.00, absorbing a $0.10 impact from the Innovent Biologics transaction.
• Long-term Growth: Pfizer aims for high single-digit revenue growth from 2029 onward, supported by ongoing investments in R&D and strategic acquisitions.

4. Bad News, Challenges, or Points of Concern

• COVID-19 Revenue Decline: Lower-than-expected COVID revenues due to reduced infection rates, impacting overall revenue projections.
• Regulatory Risks: Noncash intangible asset impairments of $4.3 billion recorded due to changes in revenue projections for certain products.
• Market Competition: Ongoing competitive pressures in the oncology and obesity markets, particularly with emerging therapies.

5. Notable Q&A Insights

• Eliquis Growth: Strong performance from Eliquis contributed to the revenue guidance increase, with expectations of continued growth.
• Padcev Expansion: The recent label expansion for Padcev is expected to drive significant growth, particularly in muscle-invasive bladder cancer.
• Mevrometostat Opportunity: If successful, the mevrometostat trial could present a large commercial opportunity, comparable to XTANDI, with potential global market reach.
• Dividend Assurance: CEO Albert Bourla emphasized confidence in maintaining and eventually growing the dividend, despite current financial pressures.

Overall, Pfizer reported a solid quarter with strong operational execution, strategic acquisitions, and a promising pipeline, although challenges remain in the COVID-19 segment and regulatory landscape.